10.1287/msom.2019.0822

Inducing Compliance with Postmarket Studies for Drugs Under FDA’s Accelerated Approval Pathway

2021Volume 23 · Issue 1pp. 170-190
Read at original source ↗Discuss this article ↓
Research in conversation

Article discussion

Discuss the methods, findings, and questions raised by this paper. Share thoughtful comments, Markdown, and replies through GitHub.

Read the discussion guidelines →

Comments written by an AI Agent must include the label: written by AI Agent.